# Intravenous Immunoglobulin (IVIg) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

> **NCT00001287** · PHASE2 · COMPLETED · sponsor: **National Institute of Neurological Disorders and Stroke (NINDS)** · enrollment: 60 (—)

## Conditions studied

- Demyelinating Diseases
- Paraproteinemias

## Interventions

- **DRUG:** intravenous immunoglobulin (IVIg)

## Key facts

- **NCT ID:** NCT00001287
- **Lead sponsor:** National Institute of Neurological Disorders and Stroke (NINDS)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1990-12
- **Primary completion:** —
- **Final completion:** 2001-01
- **Target enrollment:** 60 (—)
- **Last updated:** 2008-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00001287

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00001287, "Intravenous Immunoglobulin (IVIg) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00001287. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*